腹腔热灌注化疗在晚期卵巢上皮性癌中的疗效  

Therapeutic Effect of Intraperitoneal Hyperthermic Perfusion Chemotherapy in Epithelial Ovarian Cancer

作　　者：翟红岩[1] ZHAI Hongyan(Department of Gynecologic Oncology, Taian Cancer Prevention and Treatment Hospital, Taian Shandong 271000, China)

机构地区：[1]山东省泰安市肿瘤防治院妇瘤科

出　　处：《中国继续医学教育》2019年第21期88-90,共3页China Continuing Medical Education

摘　　要：目的探讨在腹腔热灌注化疗在晚期卵巢上皮癌中的应用价值。方法选取我院2017年10月—2018年10月临床上收治的74例晚期卵巢上皮性癌患者作为研究对象。其中37例患者术后行腹腔热灌注化疗联合静脉化疗作为观察组,另外37例患者运用静脉化疗作为对照组,观察两组临床疗效、术后不良反应、腹腔积液控制情况、CA125变化情况。结果观察组中的近期疗效、不良反应发生率、腹腔积液控制情况、CA125变化情况均优于对照组,两组比较,差异有统计学意义(P<0.05)。结论腹腔热灌注化疗可提高临床疗效,降低不良反应,改善患者生存质。Objective To explore the value of intraperitoneal hyperthermic perfusion chemotherapy in ovarian epithelial cancer. Methods 74 patients with advanced epithelial ovarian cancer treated in our hospital from October 2017 to October 2018 were selected as the study subjects. 37 patients received intraperitoneal hyperthermic perfusion chemotherapy combined with intravenous chemotherapy as observation group. Another 37 patients were treated with intravenous chemotherapy as control group. The clinical efficacy, adverse reactions, control of peritoneal effusion and changes of CA125 were observed. Results The short-term curative effect, incidence of adverse reactions, control of peritoneal effusion and changes of CA125 in the observation group were better than those in the control group. There was a significant difference between the two groups (P < 0.05). Conclusion Intraperitoneal hyperthermic perfusion chemotherapy can improve clinical efficacy, reduce adverse reactions, and improve the quality of life of patients.

关 键 词：热灌注化疗 卵巢上皮性癌 静脉化疗 肿瘤细胞减灭术 化疗毒副反应 生存情况 

分 类 号：R737.31[医药卫生—肿瘤]